



RX.PA.009.CCH DUCHENNE MUSCULAR DYSTROPHY DRUG THERAPIES

The purpose of this policy is to define the prior authorization process for Amondys 45 (casimersen), Elevidys (delandistrogene moxeparvovec-rokl), and Vyondys 53 (golodirsen).

Amondys 45 (casimersen) is indicated for the treatment of Duchenne muscular dystrophy (DMD) in patients who have a confirmed mutation of the DMD gene that is amenable to exon 45 skipping.

Vyondys 53 (golodirsen) is indicated for the treatment of Duchenne muscular dystrophy (DMD) in patients who have a confirmed mutation of the DMD gene that is amenable to exon 53 skipping.

Elevidys (delandistrogene moxparvovec-rokl) is indicated for the treatment of ambulatory pediatric patients aged 4 through 5 years with Duchenne muscular dystrophy (DMD) with a confirmed mutation in the DMD gene. This indication is approved under accelerated approval based on expression of ELEVIDYS microdystrophin in skeletal muscle observed in patients treated with ELEVIDYS. Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial(s).

For Exondys 51 (eteplirsen) – refer to the HFS criteria at <https://hfs.illinois.gov/content/dam/soi/en/web/hfs/sitecollectiondocuments/exondys51webcriteria.pdf>

DEFINITIONS

Duchenne muscular dystrophy (DMD) - is a rare, X-linked, recessive, life-threatening, degenerative neuromuscular disease affecting males. It is attributed to mutations in the DMD gene (chromosome Xp21), which is responsible for producing the protein dystrophin. Dystrophin is needed for proper muscle functioning and provides mechanical stability to muscle fibers during muscle contraction. The absence of or defect in this protein, leads to progressive muscle degeneration with loss of independent ambulation, as well as respiratory and cardiac complications.

POLICY

It is the policy of the Health Plan to maintain a prior authorization process that promotes appropriate utilization of specific drugs with potential for misuse or limited indications.

This process involves a review using Food and Drug Administration (FDA) criteria to make a determination of Medical Necessity, and approval by the Medical Policy Committee.

The drugs, Amondys 45, Elevidys, and Vyondys 53, are subject to the prior authorization process.

PROCEDURE

Initial Authorization Criteria:

Must meet all the criteria listed below:

AMONDYS 45 & VYONDYS 53

- Must have a diagnosis of Duchenne Muscular Dystrophy (DMD) with a confirmed mutation of a DMD gene that is amenable to:
 - Exon 45 skipping (Amondys 45)
 - Exon 53 skipping (Vyondys 53)
- Must be prescribed at a dose within the manufacturer's dosing guidelines (based on diagnosis, weight, etc.) listed in the FDA approved labeling
- Must be prescribed by, or in consultation with, a provider board certified in ONE of the following specialties:
 - Neurology
 - Orthopedics
 - Physical medicine and rehabilitation
 - Neuromuscular medicine
 - Neurodevelopmental disabilities
- Must have documentation of ALL the following:
 - Current weight
 - 6-Minute Walk Test (6MWT) if ambulatory
 - Brooke Upper Extremity (BUE) Function score of ≤ 5
 - Stable pulmonary function with Forced Vital Capacity (FVC) $\geq 30\%$ predicted
 - Urinalysis showing absence of proteinuria
 - Blood Urea Nitrogen (BUN)
 - Serum Creatinine (SCr)
- Must have tried (and been adherent) to standard corticosteroid therapy for a minimum of 6 months OR must have justification for discontinuation of standard therapy
- Must have documentation of the goals of therapy

ELEVIDYS

- Must be age 4 to 5 years of age at initiation of therapy
- Must have a diagnosis of Duchenne Muscular Dystrophy (DMD) with documentation of the following:
 - A mutation of the DMD gene
 - The mutation is NOT a deletion in exon 8 or exon 9
- Must be prescribed by, or in consultation with, a provider board certified in ONE of the following specialties:
 - Neurology
 - Orthopedics
 - Physical medicine and rehabilitation
 - Neuromuscular medicine
 - Neurodevelopmental disabilities
- Must be prescribed at a dose within the manufacturer's dosing guidelines (based on diagnosis, weight, etc.) listed in the FDA approved labeling
- Must have a baseline anti-AAVrh74 total binding antibody titer of < 1:400
- Must have documentation that the member is ambulatory
- Must have attestation from the provider that:
 - The member will initiate a corticosteroid regimen prior to infusion and that treatment will continue for a minimum of 60 days after infusion
 - The member will not be receiving exon-skipping therapies (e.g., Amondys 45, Exondys 51) for DMD concomitantly or following Elevidys treatment
 - The member has not received Elevidys previously

Reauthorization Criteria (AMONDYS 45 & VYONDYS 53 ONLY):

All prior authorization renewals are reviewed on an annual basis to determine the Medical Necessity for continuation of therapy. Authorization may be extended at 1-year intervals based upon chart documentation of the following:

- Must continue to be adherent to the requested medication – infusion records are required to support adherence
- Must have a clinical response to therapy, based upon the prescriber's assessment while on therapy
- Must submit current:
 - Weight
 - 6MWT if ambulatory
 - BUE Function score of ≤5
 - FVC ≥30% predicted
 - Urinalysis showing absence of proteinuria

- BUN
- SCr
- Must have continued standard therapy previously initiated (if appropriate/tolerated)

Limitations:

Length of Authorization (if above criteria met)	
Initial Authorization	Amondys 45 & Vyondys 53: Up to 1 year Elevidys: Up to 3 months
Reauthorization	Amondys 45 & Vyondys 53: Same as initial Elevidys: N/A

If the established criteria are not met, the request is referred to a Medical Director for review, if required for the plan and level of request.

Codes:

CPT Codes / HCPCS Codes / ICD-10 Codes		
Code	Brand	Description
J1426	Amondys 45	Injection, casimersen, 10mg
J1413	Elevidys	Injection, delandistrogene moxeparvovec-rokl, per therapeutic dose
J1429	Vyondys 53	Injection, golodirsen, 10mg

References:

1. Vyondys 53 [prescribing information]. Sarepta Therapeutics, Cambridge, MA, December 2019.
2. Amondys 45 [prescribing information]. Sarepta Therapeutics, Cambridge, MA, March 2023.
3. Elevidys (delandistrogene moxeparvovec) [prescribing information]. Cambridge, MA: Sarepta Therapeutics Inc; October 2023.
4. Mendell JR, Shieh PB, McDonald CM, et al. Expression of SRP-9001 dystrophin and stabilization of motor function up to 2 years post-treatment with delandistrogene moxeparvovec gene therapy in individuals with Duchenne muscular dystrophy. *Front Cell Dev Biol.* 2023;11:1167762. doi:10.3389/fcell.2023.1167762 [PubMed [37497476](#)]
5. Zaidman CM, Proud CM, McDonald CM, et al. Delandistrogene moxeparvovec gene therapy in ambulatory patients (aged ≥4 to <8 years) with duchenne muscular dystrophy: 1-year interim results from study SRP-9001-103 (ENDEAVOR). *Ann Neurol.* 2023;94(5):955-968. doi:10.1002/ana.26755 [PubMed [37539981](#)]

Revision History

DESCRIPTION OF REVIEW / REVISION	DATE APPROVED
New Policy	01/2024
Added Elevidys	04/2024

Record Retention

Records Retention for Evolent Health documents, regardless of medium, are provided within the Evolent Health records retention policy and as indicated in CORP.028.E Records Retention Policy and Procedure.

Disclaimer

CountyCare medical payment and prior authorization policies do not constitute medical advice and are not intended to govern or otherwise influence the practice of medicine. The policies constitute only the reimbursement and coverage guidelines of CountyCare and its affiliated managed care entities. Coverage for services varies for individual members in accordance with the terms and conditions of applicable Certificates of Coverage, Summary Plan Descriptions, or contracts with governing regulatory agencies.

CountyCare reserves the right to review and update the medical payment and prior authorization guidelines in its sole discretion. Notice of such changes, if necessary, shall be provided in accordance with the terms and conditions of provider agreements and any applicable laws or regulations.

These policies are the proprietary information of Evolent Health. Any sale, copying, or dissemination of said policies is prohibited.